Antiarrhythmic therapy is more often considered in DCM patients with LMNA or RBM20 gene mutations, whereas standard heart failure therapy may be sufficient in other benign DCM patients.264, 265, 266, 267. Here, RBM20 is linked to familial dilated cardiomyopathy.